论文部分内容阅读
目的观察应用巴曲酶与低分子肝素联合治疗进展性脑梗死的疗效及安全性。方法对照组给予络泰、脑蛋白水解液,治疗组在此基础上加用巴曲酶每日5 Bu,连用4 d,同时给予低分子肝素钙2 500～5000 U 皮下注射每12 h 一次。常规应用广谱抗菌素1周,观察指标:神经功能缺损评分,治疗前,后3 d、7 d、14 d 按第四届全国脑血管病会议制定的神经功能缺损评分标准分别评分。测血小板计数、凝血酶原时间(PT)、活化部分凝血活酶时间(APTT)、纤维蛋白原(Fib)凝血酶(TT)。观察全身出血情况。结果治疗组显效率60.4%明显高于时照组的20.8%,差异具有统计学意义。结论巴曲酶与低分子肝素联合治疗进展性脑梗死是有效、安全的。
Objective To observe the efficacy and safety of the combination of batroxobin and low molecular weight heparin in the treatment of advanced cerebral infarction. Methods The control group was treated with Luotai and brain protein hydrolyzate. The treatment group was treated with Batroxobin daily for 5 days for 4 days, and the low molecular weight heparin calcium was given subcutaneously every 2 hours for 2 500 ~ 5000 U once. The routine use of broad-spectrum antibiotics for 1 week, the indicators: neurological deficit score, before treatment, 3 d, 7 d, 14 d according to the Fourth National Cerebral Vascular Disease Conference neurological deficit score standards were scored. Platelet count, prothrombin time (PT), activated partial thromboplastin time (APTT), fibrinogen (Fib) thrombin (TT) were measured. Observation of systemic bleeding. Results The effective rate of treatment group was significantly higher than 60.4% 20.8% of the control group, the difference was statistically significant. Conclusion Batroxobin and LMWH are effective and safe in treating progressive cerebral infarction.